{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:40:20Z","timestamp":1790905220410,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"DOI":"10.1007\/s11739-026-04468-x","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:07:43Z","timestamp":1784837263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-3589","authenticated-orcid":false,"given":"Giuliano","family":"Cassataro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Scriffignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa","family":"Augello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angela","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Enza","family":"D\u2019Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Puleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Cadelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Renda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Tuttolomondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"12","key":"4468_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","volume":"48","author":"T Cukierman","year":"2005","unstructured":"Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia 48(12):2460\u20132469","journal-title":"Diabetologia"},{"issue":"6","key":"4468_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/jdi.12087","volume":"4","author":"K Gudala","year":"2013","unstructured":"Gudala K, Bansal D, Schifano F, Bhansali A (2013) Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig 4(6):640\u2013650","journal-title":"J Diabetes Investig"},{"issue":"12","key":"4468_CR3","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/j.1532-5415.2011.03726.x","volume":"59","author":"DG Feil","year":"2011","unstructured":"Feil DG, Rajan M, Soroka O et al (2011) Risk of hypoglycemia in older veterans with dementia and cognitive impairment: implications for practice and policy. J Am Geriatr Soc 59(12):2263\u20132272","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"4468_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","volume":"14","author":"GJ Biessels","year":"2018","unstructured":"Biessels GJ, Despa F (2018) Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol 14(10):591\u2013604","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"4468_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(05)70284-2","volume":"5","author":"GJ Biessels","year":"2006","unstructured":"Biessels GJ, Staekenborg S, Brunner E et al (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5(1):64\u201374","journal-title":"Lancet Neurol"},{"issue":"2","key":"4468_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(03)00305-3","volume":"2","author":"JT O\u2019Brien","year":"2003","unstructured":"O\u2019Brien JT, Erkinjuntti T, Reisberg B et al (2003) Vascular cognitive impairment. Lancet Neurol 2(2):89\u201398","journal-title":"Lancet Neurol"},{"issue":"1","key":"4468_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/0033354919893030","volume":"135","author":"ML Adams","year":"2020","unstructured":"Adams ML, Grandpre J, Katz DL, Shenson D (2020) Cognitive impairment and cardiovascular disease: a comparison of risk factors, disability, quality of life, and access to health care. Public Health Rep 135(1):132\u2013140","journal-title":"Public Health Rep"},{"issue":"6","key":"4468_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"Williamson JD, Pajewski NM, SPRINT MIND Investigators et al (2019) Effect of intensive vs standard BP control on probable dementia: A Randomized Clinical Trial. JAMA 321(6):553\u2013561","journal-title":"JAMA"},{"issue":"4","key":"4468_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, LEADER Trial Investigators et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322","journal-title":"N Engl J Med"},{"issue":"19","key":"4468_CR10","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, SUSTAIN-6 Investigators et al (2016) Semaglutide and cardiovascular outcomes in Type 2 Diabetes. N Engl J Med 375(19):1834\u20131844","journal-title":"N Engl J Med"},{"issue":"10157","key":"4468_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, Harmony Outcomes committees and investigators et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529","journal-title":"Lancet"},{"issue":"10193","key":"4468_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130","journal-title":"Lancet"},{"issue":"3","key":"4468_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dom.13553","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Mosenzon O, Arechavaleta R et al (2019) Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes Metab 21(3):499\u2013508","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"4468_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK et al (2015) Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab 4(10):718\u2013731","journal-title":"Mol Metab"},{"issue":"1","key":"4468_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/23312025.2016.1229086","volume":"2","author":"MK Holt","year":"2016","unstructured":"Holt MK, Trapp S (2016) The physiological role of the brain GLP-1 system in stress. Cogent Biol 2(1):1229086","journal-title":"Cogent Biol"},{"issue":"4","key":"4468_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1471-4159.2004.02914.x","volume":"92","author":"E Alvarez","year":"2005","unstructured":"Alvarez E, Martinez MD, Roncero I et al (2005) The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92(4):798\u2013806","journal-title":"J Neurochem"},{"issue":"13","key":"4468_CR17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/WNR.0b013e32832fbf14","volume":"20","author":"A Hamilton","year":"2009","unstructured":"Hamilton A, H\u00f6lscher C (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. NeuroReport 20(13):1161\u20131166","journal-title":"NeuroReport"},{"issue":"4","key":"4468_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI57256","volume":"122","author":"TR Bomfim","year":"2012","unstructured":"Bomfim TR, Forny-Germano L, Sathler LB et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease-associated A\u03b2 oligomers. J Clin Invest 122(4):1339\u20131353","journal-title":"J Clin Invest"},{"issue":"2","key":"4468_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","volume":"31","author":"AM Moloney","year":"2010","unstructured":"Moloney AM, Griffin RJ, Timmons S et al (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer\u2019s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31(2):224\u2013243","journal-title":"Neurobiol Aging"},{"key":"4468_CR20","first-page":"128","volume":"3","author":"S Lee","year":"2013","unstructured":"Lee S, Tong M, Hang S et al (2013) CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer\u2019s disease. J Alzheimers Dis Parkinsonism 3:128","journal-title":"J Alzheimers Dis Parkinsonism"},{"issue":"7","key":"4468_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nrneurol.2012.112","volume":"8","author":"S Craft","year":"2012","unstructured":"Craft S (2012) Alzheimer disease: insulin resistance and AD-extending the translational path. Nat Rev Neurol 8(7):360\u2013362","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"4468_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ et al (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29\u201338","journal-title":"Arch Neurol"},{"issue":"1-3","key":"4468_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejphar.2013.08.008","volume":"719","author":"B Cholerton","year":"2013","unstructured":"Cholerton B, Baker LD, Craft S (2013) Insulin, cognition, and dementia. Eur J Pharmacol 719(1\u20133):170\u2013179","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4468_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2337\/ds16-0041","volume":"29","author":"B Cholerton","year":"2016","unstructured":"Cholerton B, Baker LD, Montine TJ et al (2016) Type 2 diabetes, cognition, and dementia in older adults: toward precision health approach. Diabetes Spectr 29(4):210\u2013219","journal-title":"Diabetes Spectr"},{"issue":"7","key":"4468_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM et al (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol 19(7):582\u2013590","journal-title":"Lancet Neurol"},{"issue":"8","key":"4468_CR26","volume":"24","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 24(8):108","journal-title":"Front Aging Neurosci"},{"key":"4468_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","volume":"207","author":"RB Mansur","year":"2017","unstructured":"Mansur RB, Ahmed J, Cha DS et al (2017) Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study. J Affect Disord 207:114\u2013120","journal-title":"J Affect Disord"},{"issue":"6","key":"4468_CR28","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2013) Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest 123(6):2730\u20132736","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"4468_CR29","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association (2020) Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43(Suppl 1):S14\u2013S31","journal-title":"Diabetes Care"},{"issue":"2","key":"4468_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255\u2013323","journal-title":"Eur Heart J"},{"issue":"39","key":"4468_CR31","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140","journal-title":"Eur Heart J"},{"key":"4468_CR32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th ed. APA, Washington, DC","edition":"5th ed"},{"issue":"5","key":"4468_CR33","first-page":"9","volume":"27","author":"A Pirani","year":"2020","unstructured":"Pirani A, Antonelli Incalzi R, Biggio G et al (2020) L\u2019approccio al paziente con declino cognitivo lieve: risultati di un\u2019indagine in Medicina Generale. Rivista SIMG 27(5):9\u201318 ((in Italian))","journal-title":"Rivista SIMG"},{"issue":"4","key":"4468_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699","journal-title":"J Am Geriatr Soc"},{"issue":"13","key":"4468_CR35","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1212\/WNL.0b013e318230208a","volume":"77","author":"HC Rossetti","year":"2011","unstructured":"Rossetti HC, Lacritz LH, Cullum CM, Weiner MF (2011) Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 77(13):1272\u20131275","journal-title":"Neurology"},{"key":"4468_CR36","volume-title":"Wechsler adult intelligence scale-revised","author":"D Wechsler","year":"1981","unstructured":"Wechsler D (1981) Wechsler adult intelligence scale-revised. Psychological Corporation, New York"},{"issue":"7","key":"4468_CR37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S2213-8587(14)70062-2","volume":"2","author":"T Cukierman-Yaffe","year":"2014","unstructured":"Cukierman-Yaffe T, Bosch J, Diaz R et al (2014) Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes Endocrinol 2(7):562\u2013572","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4468_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561\u2013571","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"4468_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0005-7967(99)00068-6","volume":"38","author":"RA Steer","year":"2000","unstructured":"Steer RA, Rissmiller DJ, Beck AT (2000) Use of the Beck Depression Inventory-II with depressed geriatric inpatients. Behav Res Ther 38(3):311\u2013318","journal-title":"Behav Res Ther"},{"key":"4468_CR40","volume-title":"Handbook of psychological assessment","author":"G Groth-Marnat","year":"1990","unstructured":"Groth-Marnat G (1990) Handbook of psychological assessment, 2nd ed. Wiley, New York","edition":"2nd ed"},{"issue":"1","key":"4468_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","volume":"8","author":"AT Beck","year":"1988","unstructured":"Beck AT, Steer RA, Garbin MG (1988) Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 8(1):77\u2013100","journal-title":"Clin Psychol Rev"},{"issue":"9 Suppl","key":"4468_CR42","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.14309\/01.ajg.0000948452.01988.0c","volume":"118","author":"K Kj\u04d5rgaard","year":"2023","unstructured":"Kj\u04d5rgaard K, Daugaard Mikkelsen AC, Bay-Richter C et al (2023) Semaglutide reduces cognitive dysfunction in experimental non-alcoholic steatohepatitis through anti-inflammatory and neuroprotective effects. Am J Gastroenterol 118(9 Suppl):S28\u2013S29","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"4468_CR43","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X et al (2024) Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement 20(12):8661\u20138672","journal-title":"Alzheimers Dement"},{"issue":"7","key":"4468_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.21016","volume":"8","author":"HT Lin","year":"2025","unstructured":"Lin HT, Tsai YF, Liao PL et al (2025) Neurodegeneration and stroke after semaglutide and tirzepatide in patients with type 2 diabetes and obesity. JAMA Netw Open 8(7):e2521016","journal-title":"JAMA Netw Open"},{"key":"4468_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf577","author":"O Atieh","year":"2025","unstructured":"Atieh O, Daher J, Abboud M et al (2025) Effects of semaglutide on cognitive function in people with human immunodeficiency virus: a randomized, controlled trial. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf577","journal-title":"Clin Infect Dis"},{"key":"4468_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113537","volume":"143","author":"N Siddeeque","year":"2024","unstructured":"Siddeeque N, Hussein MH, Abdelmaksoud A et al (2024) Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study. Int Immunopharmacol 143:113537","journal-title":"Int Immunopharmacol"},{"key":"4468_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00459-948","author":"J Cummings","year":"2026","unstructured":"Cummings J, Atri A, Sano M et al (2026) Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(26)00459-948","journal-title":"Lancet"},{"issue":"1","key":"4468_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","volume":"23","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH (2024) The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 23(1):47\u201355","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"4468_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-024-10142-w","volume":"19","author":"IHR de Paiva","year":"2024","unstructured":"de Paiva IHR, da Silva RS, Mendon\u00e7a IP et al (2024) Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain axis. J Neuroimmune Pharmacol 19(1):36","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"4468_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ et al (2020) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5(6):e133429","journal-title":"JCI Insight"},{"key":"4468_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA (2020) Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol 180:114187","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"4468_CR52","doi-asserted-by":"publisher","first-page":"E472","DOI":"10.1152\/ajpendo.00250.2023","volume":"326","author":"S Buller","year":"2024","unstructured":"Buller S, Blouet C (2024) Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss. Am J Physiol Endocrinol Metab 326(4):E472\u2013E480","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"4468_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094972","volume":"25","author":"RO Tipa","year":"2024","unstructured":"Tipa RO, Balan DG, Georgescu MT et al (2024) A systematic review of semaglutide\u2019s influence on cognitive function in preclinical animal models and cell-line studies. Int J Mol Sci 25(9):4972","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4468_CR54","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","volume":"14","author":"J West","year":"2025","unstructured":"West J, Li M, Wong S et al (2025) Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review. Neurol Ther 14(4):1157\u20131166","journal-title":"Neurol Ther"},{"key":"4468_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100916.58","author":"S Badulescu","year":"2026","unstructured":"Badulescu S, Gill H, Shah H et al (2026) Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: a randomized clinical trial. Med. https:\/\/doi.org\/10.1016\/j.medj.2025.100916.58","journal-title":"Med"},{"issue":"20","key":"4468_CR56","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, SOUL Study Group et al (2025) Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 392(20):2001\u20132012","journal-title":"N Engl J Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04468-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04468-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04468-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:01:43Z","timestamp":1784840503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04468-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":56,"alternative-id":["4468"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04468-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee Palermo 1.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}